NT_1170x120_1-11-18

Bydureon BCise

AstraZeneca releases Bydureon BCise to U.S. pharmacies

AstraZeneca releases Bydureon BCise to U.S. pharmacies

WILMINGTON, Del. — AstraZeneca announced that Bydureon BCise (exenatide extended-release injectable suspension 2 mg) is now available in pharmacies across the United States. Bydureon BCise was recently approved by the U.S. Food and Drug Administration for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral antidiabetic medicines in addition to

AstraZeneca cleared to market Bydureon BCise

AstraZeneca cleared to market Bydureon BCise

  WILMINGTON, Del. — Early next year, AstraZeneca plans to release Bydureon BCise, a new formulation of Bydureon (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector for adults with type 2 diabetes. The company said this week that it has received Food and Drug Administration approval for Bydureon BCise, indicated to improve glycemic